PDF Version
TO: Pharmacies, Physicians, Physician Assistants, Nurse Practitioners,
Oral Surgeons, Optometrists, Dentists, FQHCs, RHCs, Mental Health Service
Providers and Nursing Homes
RE: Preferred Drug List (PDL) and Pharmacy Quarterly Update
Effective April 1, 2024,
the Alabama Medicaid Agency (Medicaid) will:
1.
Continue to monitor the stimulant shortage affecting ADHD medications. Should you need
assistance, please contact Kepro at the number below for alternative prescribing
and dispensing options.
2. Require Prior Authorization (PA) for generic insulin glargine, insulin glargine max solostar, insulin glargine solostar, insulin lispro, saxagliptin, saxagliptin-metformin, and tiotropium bromide. Brand Humalog, Kombiglyze XR, Lantus, Onglyza, and Spiriva Handihaler will remain preferred. Brand Toujeo Max Solostar and brand Toujeo Solostar will remain non-preferred.
3. Require Humalog, Kombiglyze XR, Lantus, Onglyza, and Spiriva
Handihaler to be billed with a Dispense as Written (DAW) Code of 9. DAW Code of 9 indicates the following: Substitution Allowed by Prescriber
but Plan Requests Brand. This value is used when the prescriber has indicated,
in a manner specified by prevailing law, that generic substitution is permitted,
but the Plan requests the brand product to be dispensed.
4.
Implement clinical criteria for the Incretin Mimetics class.
Preferred agents will be preferred with clinical criteria. Preferred products must meet clinical
criteria to include FDA approved indications in order to be approved. Non-preferred
products will require prior authorization.
5. Update the PDL to reflect the
quarterly updates listed below:
PDL
Additions
|
Apidra
|
Insulins
|
Apidra Solostar
|
Insulins
|
Bydureon Bcise CC
|
Incretin Mimetics
|
Ozempic CC
|
Incretin Mimetics
|
Rybelsus CC
|
Incretin Mimetics
|
PDL Deletions
|
Clindesse
|
Skin
Mucous Membrane Agents Antibacterials
|
insulin
glargine max solostar
|
Insulins
|
insulin
glargine solostar
|
Insulins
|
saxagliptin
HCL
|
Dipeptidyl
Peptidase-4 (DPP-4)
|
saxagliptin-metformin
ER
|
Dipeptidyl
Peptidase-4 (DPP-4)
|
tiotropium
bromide
|
Inhaled
Antimuscarinics
|
Tudorza
Pressair
|
Inhaled
Antimuscarinics
|
CC This agent will be preferred with clinical criteria in place.
For additional
PDL and coverage information, visit our drug look-up site at https://www.medicaid.alabamaservices.org/alportal/NDC%20Look%20Up/tabId/5/Default.aspx
The Prior Authorization (PA) request form and criteria booklet should
be utilized by the prescriber or the
dispensing pharmacy when requesting a PA. The
PA request form can be completed and submitted
electronically at
https://medicaid.alabama.gov/content/9.0_Resources/9.4_Forms_Library/9.4.13_Pharmacy_Forms.aspx.
Providers requesting PAs by
mail or fax should send requests to:
Kepro
Medicaid
Pharmacy Administrative Services
P.O.
Box 3570, Auburn, AL 36831
Fax:
1-800-748-0116
Phone:
1-800-748-0130
Incomplete PA requests or
those failing to meet Medicaid criteria will be denied. If the prescriber believes
medical justification should be considered, the prescriber must document this
on the form or submit a written letter of medical justification along with the
PA form to Kepro. Additional information may be requested. Staff physicians will
review this information.
The Current Procedural Terminology (CPT) and Current Dental Terminology
(CDT) codes descriptors, and other data are copyright © 2024
American Medical Association and © 2024 American Dental Association (or such other date publication of CPT and
CDT). All rights reserved. Applicable FARS/DFARS apply.